Coupling machine learning and high throughput multiplex digital PCR enables

accurate detection of carbapenem-resistant genes in clinical isolates

Luca Miglietta[1,2,†], Ahmad Moniri[2,†], Ivana Pennisi[1], Kenny Malpartida-Cardenas[2],

Hala Abbas[3], Kerri Hill-Cawthorne[1], Frances Bolt[1], Frances Davies[1,3], Alison

Holmes[1,3], Pantelis Georgiou[2] and Jesus Rodriguez-Manzano[1,*]

[1] Department of Infectious Disease, Faculty of Medicine, Imperial College London, UK.

[2] Department of Electrical and Electronic Engineering, Faculty of Engineering, Imperial

College London, UK.

[3] Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.

[†]Luca Miglietta and Ahmad Moniri contributed equally.

*Address correspondence to this author at: Room 8N9, Commonwealth Building,

Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN; Email:

j.rodriguez-manzano@imperial.ac.uk

Background: The emergence and spread of carbapenemase-producing organisms

(CPO) are a significant clinical and public health concern. Rapid and accurate

identification of patients colonised with CPO is essential to adopt prompt prevention

measures in order to reduce the risk of transmission. Recent proof-of-concept studies

have demonstrated the ability to combine machine learning (ML) algorithms with real-

time digital PCR (dPCR) instruments to increase classification accuracy of multiplex

assays. From this, we sought to determine if this ML based methodology could

accurately identify five major carbapenem-resistant genes in clinical CPO-isolates.

Methods: We collected 253 clinical isolates (including 221 CPO-positive samples) and

developed a novel 5-plex assay for detection of bla_{VIM}, bla_{OXA-48}, bla_{NDM}, bla_{IMP} and

bla_{KPC}. Combining the recently reported ML method 'Amplification and Melting Curve

Analysis' (AMCA) with the abovementioned multiplex assay, we assessed the

performance of the methodology in detecting these five carbapenem-resistant genes.

The classification accuracy relies on the usage of real-time data from a single

fluorescent channel and benefits from the kinetic and thermodynamic information

encoded in the thousands of amplification events produced by high throughput dPCR.

Results: The 5-plex showed a lower limit of detection of 100 DNA copies per reaction

for each primer set and no cross-reactivity with other carbapenemase genes. The

AMCA classifier demonstrated excellent predictive performance with 99.6% (CI 97.8-

99.9%) accuracy (only one misclassified sample out of the 253, with a total of 163,966

positive amplification events), which represents a 7.9% increase compared to the

conventional ML-based melting curve analysis (MCA) method.

Conclusion: This work demonstrates the utility of the AMCA method to increase the

throughput and performance of state-of-the-art molecular diagnostic platforms,

reducing costs without any changes to instrument hardware. Our findings suggest that,

pending additional validation directly from clinical samples, advanced data-driven

multiplex dPCR could potentially be integrated in routine clinical diagnostic workflows.

Introduction

This paper shows that machine learning (ML) approaches coupled with high throughput real-time digital PCR (dPCR) can be used to increase detection accuracy of multiplex assays. We used a recently reported ML method called Amplification and Melting Curve Analysis (AMCA), which leverages the target-specific information encoded in each amplification event (via real-time data), to identify the nature of nucleic acid molecules (1). Validation of this methodology using clinical isolates has never been reported before. Nucleic acid amplification tests (NAATs) that incorporate the AMCA classifier for multiple target detection will greatly improve their specificity, sensitivity and turn-around times, reducing overall resource consumptions.

Antimicrobial resistance (AMR) is a serious global threat and poses a challenge for modern medicine, compromising effective infectious disease management (2,3). One of the most concerning forms of AMR is the rapid spread of carbapenemase-producing organisms (CPOs); bacteria producing enzymes that inactivate the potent antibiotics, carbapenems. Whilst overall UK incidence is low, there are centres nationally facing increasing rates and outbreaks, including Imperial College Healthcare NHS Trust (ICHNT), and it is endemic in many other regions worldwide (4,5). CPO infections are associated with higher morbidity and mortality than susceptible strains, in part because their resistance can lead to ineffective empirical therapy and suboptimal treatment (6). Therapeutic options are severely restricted, and in many cases clinical management relies on "last line" antibiotics that are less effective and have more side effects (7).

CPO infections present significant challenges for diagnostics and infection control. There is an urgent need for accurate and timely diagnosis of CPO infections to improve patient outcomes and prevent the spread of AMR. Carbapenemase resistance genes

are often co-localised on highly transmissible plasmids and are readily shared

between bacterial species, providing the ideal conditions for multidrug resistant

organisms. Incorrect diagnosis delays appropriate intervention, increases financial

burdens for the healthcare system and complicates antimicrobial stewardship efforts.

A local ICHNT economic analysis estimated the cost of a large hospital outbreak (~100

infections) of carbapenemase producing *Klebsiella pneumoniae* to be £1M. Some of

the increased expenditure was associated with increased screening, bed closures,

medication and patient bed-days (8).

CPO diagnostics is typically complicated and is often based upon multiple tests which

utilise a wide range of instruments. Phenotypic methods typically target

carbapenemase production and provide no information on the underlying resistance

mechanism (9). These tests represent a low-cost (£2-15 per sample) and robust

methodology; however, they rely on pure culture which increases turnaround times

(12-24h) (10). A variety of molecular methods, including amplification, microarray and

sequencing assays have been developed and are frequently used in microbiology

laboratories (11,12). Microarray and sequencing are time consuming (>12-48h),

expensive (>£50K platforms and >£80 per sample), and require bioinformatic

expertise and dedicated personnel, which often limits its implementation into routine

practice. Conversely, NAATs are cheaper (£18K instruments and £15-30 per sample)

and faster (1-2h), however, their performance has been suboptimal for challenging

diagnostic scenarios (e.g. outbreak investigation), and the application of sophisticated

data processing for its optimisation (as done with the other two methods) has been

largely unexplored (13).

Recently, our group has demonstrated that the large volume of data obtained from

real-time digital PCR (dPCR) instruments can be exploited to perform data-driven

multiplexing in a single fluorescent channel, reporting a 99.28% accuracy of target

identification when using synthetic DNA in a 9-plex format (1). The ML method used,

called AMCA, leverage kinetic and thermodynamic information encoded in the

amplification and melting curves, to perform target identification in multiplexed

environments (14,15,16). Here we evaluate, for the first time, the performance of the

AMCA methodology for detection of the most common types of serine-beta-lactamase

(bla_{KPC} and bla_{OXA-48}) and metallo-beta-lactamase (bla_{IMP}, bla_{VIM} and bla_{NDM}) in clinical

isolates (17,18). Results were compared against another ML based classifier called

melting curve analysis (MCA), which only uses the thermodynamic information for

identification of multiple targets in a single well reaction (1,19). A 5-plex PCR assay

was developed in-silico and validated with synthetic DNA templates. The performance

of the AMCA method, using this 5-plex, was further assessed with 253 clinical isolates

provided by the Microbiology Department at Charing Cross Hospital, ICHNT. All

samples were classified in dPCR, using an intercalating dye (EvaGreen) in a single-

fluorescent channel. This work demonstrates that the AMCA method can be integrated

with conventional clinical diagnostic workflows in combination with real-time dPCR

platforms (Figure 1), as it does not require any hardware and only standard operation

modification.

Materials and Methods

Synthetic DNA

Double-stranded synthetic DNA (gBlock Gene fragments) containing the entire coding

sequences of bla_{IMP}, bla_{KPC}, bla_{NDM}, bla_{OXA-48} and bla_{VIM} was used. The gene

fragments (ranging from 900 to 1000 bp) were purchased from IDT and resuspended

in Tris−EDTA buffer to 10 ng/µL stock solutions (stored at −80 °C until further use).

The concentrations of all DNA stock solutions were determined using Nanodrop (Life

Technologies). The following NCBI accession numbers are used as reference for the

gBlock synthesis: NG_049172 (bla_{IMP}), NC_016846 (bla_{KPC}), NC_023908 (bla_{NDM}),

NG_049762 (bla_{OXA-48}) and NG_050336 (bla_{VIM}).

Bacterial strains and culture condition

A total of 253 non-duplicated *Enterobacteriaceae* isolates were collected between

2012-2020 from clinical or screening samples routinely processed by Microbiology

Department at Charing Cross Hospital, ICHNT (Ethics protocol 06/Q0406/20). Species

identification was performed using MALDI-TOF MS and carbapenemase mechanisms

were determined using the Xpert Carba-R (Cepheid) or Resist-3 O.K.N assay

(Corisbio). The isolates were subcultured on appropriate growth media and incubated

at 37 °C overnight, and the genomic DNA was extracted using GenElute Bacterial

Genomic DNA kit (Sigma-Aldrich) following the manufacturer's instructions.

Primer Design

The genes used in this study belong to (i) class A carbapenemase encoding for KPC

type, (ii) class D oxacillinases encoding OXA-48 and (iii) class B metalloenzymes

encoding NDM, IMP and VIM. The sequences of these genes were downloaded from

the GenBank web site (http://www.ncbi.nlm.nih.gov/genbank/). Based on the

comprehensive analyses and alignments of each carbapenemase type using the

MUSCLE algorithm (20), primers were specifically designed to amplify all alleles of

each carbapenemase gene family described above. Design and in-silico analysis were

conducted using GENEious Prime 2020.1.2 (https://www.geneious.com). Primer

characters were analysed through IDT OligoAnalyzer software

(https://eu.idtdna.com/pages/tools/oligoanalyzer) using the J. SantaLucia

thermodynamic table for melting temperature (T_m) evaluation, hairpin, self-dimer, and

cross-primer formation (21). The T_m of the amplification product of each gene was

determined by Melting Curve Predictions Software (uMELT) package (https://dna-

utah.org/umelt/umelt.html). To confirm the specificity of the real-time digital PCR

assays, the primers were evaluated in a singleplex PCR to ensure that they correctly

amplified their respective loci and that the amplicons showed the expected T_m. All

primers were synthesized by IDT (Coralville, IA, USA). Primer sequences and

amplicon information are listed in Table 1.

Multiplex real-time digital PCR

Each amplification reaction was performed in 4 µL of final volume with 2 µL of SsoFast

EvaGreen Supermix with Low ROX (BioRad, UK), 0.4 µL of 20X GE Sample Loading

Reagent (Fluidigm PN 85000746), 0.2 µL of PCR grade water, 0.2 µL of 20X multiplex

PCR primer mixture containing the three primer sets (10 µM of each primer), and 1.2

µL of different concentrations of synthetic DNA (or controls). PCR amplifications

consisted of a hot start step for 10 min at 95°C, followed by 45 cycles at 95°C for 20

s, 67°C for 45 s, and 72°C for 30 s. Melting curve analysis was performed with one

cycle at 65°C for 3 s and reading from 65 to 97°C with an increment of 0.5°C. We used

the integrated fluidic circuit controller to prime and load qdPCR 37K digital chips and

Fluidigm's Biomark HD system to perform the dPCR experiments, following

manufacturer's instructions. More specifically, each digital chip contains 48 inlets,

where each inlet is connected a panel consisting of 770 wells (0.85 nL well volume)

(22). In this study, we used 7 digital chips, totalling 336 panels.

Analytical sensitivity for the 5-plex assay

Limit-of-detection (LOD) for each primer set in the multiplex format was evaluated with

10-fold dilutions of synthetic DNA containing the 5 carbapenemase genes, ranging

from 10^1 to 10^7 copies per reaction. Each experimental condition was run in triplicate

using a qPCR platform (LightCycler 96, LC96). Data was analysed using LC96 System

software version SW1.1 (Supplemental Figure 1).

ML-based MCA and AMCA methods

The proposed method, referred to as AMCA, trains a supervised machine learning

model to combine the predictions of ACA and MCA as reported in previous studies

from Moniri et al. (1,14). In this study, the MCA method consists of applying a logistic

regression model to melting T_m values extracted from each melting curve. The ACA

consists of applying a k-nearest neighbors (KNN) model (with parameter k=10) to the

entire real-time curve from each amplification event. Both MCA and ACA output 5

probabilities associated with each target in the 5-plex. Therefore, these probabilities

are concatenated into 10 values which are the input to the AMCA method (which is a

linear regression model). It is important to note that this classifier is tuned with its own

cross-validation step in order to avoid overfitting.

Statistical Analysis

Prior to conducting this study, a sufficient number of samples was determined to

provide statistically significant results via the binomial proportion confidence interval

method (23). Under the assumption that the test has a sensitivity and specificity of

95% with a 5% margin of error, the number of samples were determined as 72 (which

is significantly smaller than 221 used in this study).

Performance of the models was determined by training on synthetic DNA and testing

on the aforementioned 221 isolates. Alongside evaluating the performance of the

models on the isolates, performance of the models was also estimated based on out-

of-sample classification accuracy, as determined by 10-fold cross-validation on the

training data (using stratified splits). The two-sided t-test with unknown variances was

used to determine statistical significance for comparing the classification accuracy of

AMCA against MCA. Prior to this test, a Lilliefors test was used to determine normality

of the distributions and the Bartlett test for equal/unequal variances. A *p*-value of 0.05

was used as a threshold for statistical significance for all tests.

Results

Primer characterisation for optimal multiplex assay performance

(i) _in-silico analysis_. To test the inclusivity and exclusivity of the 5-plex assay, primers

were subjected to a general NCBI BlastN search against more than 500 sequences

per target. Inclusivity results showed over 99% identity coverage for each target

(inclusivity alignments are provided in Supplemental Figure 2-6). For exclusivity

analysis, BlastN hits with an identity score lower than 80% were regarded as negative.

No cross-reactivity was observed with other sequences deposited in the database.

(ii) _experimental results in qPCR_. The 5-plex has been validated using a conventional

qPCR platform with synthetic DNA templates at concentrations ranging from 10^2 to

10^7 DNA copies/reaction. Supplemental Figure 1 shows the real-time amplification (a),

melting (b) and standard curves (c). The amplification and melting curves have distinct

shape for each target, which is beneficial for AMCA classification, and the observed

T_m values for bla_{IMP}, bla_{KPC}, bla_{NDM}, bla_{OXA-48} and bla_{VIM} are 81.4, 89.5, 90.2, 83.8 and

87.9°C, respectively. Moreover, each primer set (in a multiplex environment) shows

an excellent LOD of 100 DNA copies/reaction. Corresponding standard curves,

illustrating the C_q value as a function of the target concentration, yield an assay

efficiency of 87.3, 103.5, 105.7, 98.7, 88.1%, respectively.

(iii) *experimental results in dPCR*. The 5-plex was further validated in dPCR platform

with synthetic DNA templates at concentrations ranging from 10^2 to 10^7 DNA

copies/reaction, as depicted in Figure 2. A total of 29,165 amplification reactions were

performed. In Figure 2, a and b show respectively the amplification and melting curves

for the five carbapenem-resistant genes and the average characteristic shape for each

target (black solid line). Figure 2c represents the distribution of melting temperature in

real-time dPCR, where the T_m range for each target is computed as: bla_{IMP} (81.3,

83.2°C), bla_{KPC} (89.0, 91.5°C), bla_{NDM} (90.0, 92.7°C), bla_{OXA-48} (83.7, 86.6°C) and

bla_{VIM} (87.7, 90.8°C).

Samples

As depicted in Table 2, the 253 pure bacterial strains were identified from MALDI-TOF

MS as *Acinetobacter* spp. (n = 2), *Citrobacter* spp. (n = 16), *Enterobacter* spp. (n =

37), *Escherichia* spp. (n = 57), *Klebsiella* spp. (n = 133), *Proteus* sp. (n = 1),

Pseudomonas sp. (n = 5) and *Serratia* sp. (n = 2). Carbapenemase genes were

determined as a single enzyme in 220 strains (bla_{IMP} = 45; bla_{KPC} = 9; bla_{NDM} = 74;

bla_{OXA-48} = 84; bla_{VIM} = 8) and as a combination in one isolate (bla_{NDM} & bla_{OXA-48}).

Thirty-two isolates were confirmed as negative for the five carbapenemase genes. A

more detailed description of each isolate, including bacterial species, date of sampling,

specimen type and antibiotic resistance mechanisms can be found in Supplemental

Table 1.

The AMCA model: training and cross-validation

Our study aims to validate the performance of the AMCA method for detection of

carbapenem-resistant genes in clinical isolates. Results obtained from AMCA were

compared with the MCA approach. To train both models, a total of 99,860 amplification

events were generated using synthetic DNA templates, of which 29,165 were positive:

bla_{IMP} (N=4,227), bla_{KPC} (N=3,993) bla_{NDM} (N=3,500), bla_{OXA-48} (N=3,771) and bla_{VIM}

(N=4,596). Training dataset performance is shown in Supplemental Figure 7 with

relative accuracies and sample sizes.

The AMCA model: clinical validation

A total of 253 clinical isolates, including 221 positives, and 227,150 amplification

events (of which 163,966 positives) were used for the clinical validation. The overall

observed accuracy for MCA was 91.7% (CI 87.59 to 94.79%) and 99.6% (CI 97.82%

to 99.99%) for AMCA, which represent a 7.9% increase. A total of 21 samples were

misclassified for the MCA method and considered false positives (FP) as shown in

Table 3, whereas the AMCA reduced the number of misclassified samples to 1 (Table

4). All the false positive samples were identified as double infection because of the

overlapping distribution in the melting T_m, as shown in Figure 2. Performance

improvement in the AMCA method is due to the addition of real-time amplification data,

contrary to the MCA approach that only takes into account the melting curve

distribution (Supplemental Figure 8). Moreover, 32 bacterial isolates not carrying the

five carbapenemase genes were used to evaluate the assay specificity. The 5-plex

assay showed negative results in the absence of the specific target.

Discussion

In the last decade, novel pandemic outbreaks and the continued threats of emerging

multi-drug resistant microorganisms have increased the requirement of PCR tests for

diagnosis. Therefore, alternative methods are necessary to accelerate infection

source identification, especially in countries where the number of laboratory

capabilities is limited. The AMCA technology is designed to provide a high-throughput

and cost-effective testing for a large range of urgent antibiotic resistance threats in a

single well reaction. Seamlessly integrated with conventional diagnostic workflows,

this machine learning based approach can enhance multiplexing capabilities of

traditional qPCR and dPCR instruments, which already existing in laboratories around

the world. In this paper, we performed a clinical validation of the AMCA methodology

by targeting the "big five" carbapenem-resistant gene in multiplex PCR: bla_{VIM}, $bla_{OXA\text{-}48}$,

bla_{NDM}, bla_{IMP} and bla_{KPC}. The performance was evaluated in both real-time PCR

and digital PCR instruments, and further investigated through the identification of 253

clinical isolates form patients affected by different pathogenic species. We found 221

CPO-positive samples for the mentioned targets across multiple bacterial species.

As previously reported (1), the AMCA method is capable of enhancing high-level

multiplexing capabilities in real-time dPCR platforms, increasing the classification

accuracy by utilising kinetic and thermodynamic information of the amplification event.

The methodology is extremely advantageous to identify multiple targets in a single

reaction in a time and cost-effective manner. In this study, we compared the

classification performance of two machine learning based methods, MCA and AMCA,

using five carbapenem-resistant genes. Our objective was to evaluate the benefit of

advance data analytics applied to conventional diagnostic workflows for AMR. In the

first instance, we addressed the MCA method performance; it can be observed that

this approach is limited by the thermodynamic nature of the reaction, which negatively

influences both sensitivity and accuracy of the multiplex assay. The visualisation of

the melting peak distribution showed the presence of overlapping regions (e.g. bla_{NDM}

and bla_{KPC}). This phenomenon can compromise the classification based purely on

melting curves, with further complication in double-infections events. However, this

effect is reduced with AMCA method as it benefits from the kinetic information of the

amplification event, which makes the method more reliable and reduces the need for

lengthy assay optimisation.

Generally, digital PCR offers a number of clear advantages compared to qPCR,

representing an attractive alternative tool for molecular diagnostics (24). Due to its

high throughput and the single molecule environment, dPCR is extremely suitable for

machine learning based algorithm and high-level multiplex assays, which further

increases the diagnostic capabilities and enables multiple infection detection (14).

Main disadvantages of dPCR are related to the complexity in the experimental setup

and the slower turn-around time. However, single molecule measurements decrease

inhibition and reagent costs per test, and the high throughput data results in more

reliable and accurate sample classification. Coupling dPCR instrument with data-

driven multiplexing in diagnostic setups, will facilitate sample identification and

generally more robust molecular diagnosis.

Although the results in this manuscript present a milestone towards providing a fast,

reliable and cost-effective diagnostic solution for multiplexed assays, there are several

aspects that need to be further investigated. Firstly, in this paper we evaluate the performance of AMCA method in clinical isolates using pure bacterial cultures. A follow-up study will address the performance of the method directly from clinical samples. Secondly, it is important to identify co-presence of infections for patient treatment, however in this paper we address only one sample with a double infection; a larger study will be required to test the effectiveness of the AMCA in double pathogen identification. Depending on the sample concentration, this might not limit multiplexing capabilities in digital PCR, but it could represent a challenge when qPCR instruments are used.

This work suggests that the AMCA approach provides a versatile solution for the rapid detection of AMR genes and delivers reliable, fast and cost-effective results in diagnostic pipelines. This study highlights how important is the integration of artificial intelligence (AI) for diagnosis and how effectively it increases result reliability of state-of-the-art dPCR instruments. Moreover, the AMCA methodology has the potential for further application in point-of-care devices and isothermal chemistries, as a solution to leverage identification accuracy and enable faster detection of several pathogens.

Supplemental Material

Supplemental material is available at *Clinical Chemistry* online.

Nonstandard abbreviations: qdPCR, real-time digital PCR; dPCR, digital PCR; qPCR, quantitative real-time PCR; LOD, limit of detection, C_q, quantitation cycle; T_m, melting temperature; ICHNT, Imperial College Healthcare NHS Trust; CPO, Carbapenemase-Producing Organisms; AMR, Antimicrobial Resistance: ACA,

Amplification Curve Analysis; MCA, Melting Curve Analysis; AMCA, Amplification and

Melting Curve Analysis; KNN, k-nearest neighbors.

Author Contributions: *All authors confirmed they have contributed to the intellectual*

content of this paper and have met the following 4 requirements: (a) significant

contributions to the conception and design, acquisition of data, or analysis and

interpretation of data; (b) drafting or revising the article for intellectual content; (c) final

approval of the published article; and (d) agreement to be accountable for all aspects

of the article thus ensuring that questions related to the accuracy or integrity of any

part of the article are appropriately investigated and resolved.

Ethical Approval: All the isolate samples were collected from clinical or screening

samples routinely processed by the hospital Microbiology Department at Imperial

College Healthcare NHS Trust (Ethics protocol 06/Q0406/20).

Data and Code Availability: All data and code used in this study can be found at:

https://github.com/Luca/pyAMCA_5plex.

Acknowledgments: This work was supported by NIHR Imperial Biomedical Research

Centre [P80763]; [Co-]funded/supported by the Medical Research Council [grant

number MR/T005254/1] and EPSRC DTP (EP/ N509486/1 to A.M. and K.M.C.). The

research was partially funded by the DHSC Centre for Antimicrobial Optimisation

(CAMO) at Imperial College London. The views expressed in this publication are those

of the authors and not necessarily those of the Department of Health and Social Care,

NHS, or the National Institute for Health Research. HA was sponsored by the Imperial

References

1. Moniri A, Miglietta L, Holmes A, Georgiou P, Rodriguez-Manzano J. High-Level

Multiplexing in Digital PCR with Intercalating Dyes by Coupling Real-Time Kinetics

and Melting Curve Analysis. Anal Chem. 2020;92:14181–8.

2. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL.

Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: An

evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25:682–707.

3. Bush K, Fisher JF. Epidemiological Expansion, Structural Studies, and Clinical

Challenges of New β-Lactamases from Gram-Negative Bacteria. Annu Rev Microbiol.

Annual Reviews; 2011;65:455–78.

4. Otter JA, Doumith M, Davies F, Mookerjee S, Dyakova E, Gilchrist M, et al.

Emergence and clonal spread of colistin resistance due to multiple mutational

mechanisms in carbapenemase-producing Klebsiella pneumoniae in London. Sci

Rep. 2017;7:1–8.

5. Rodriguez-Manzano J, Moser N, Malpartida-Cardenas K, Moniri A, Fisarova L,

Pennisi I, et al. Rapid Detection of Mobilized Colistin Resistance using a Nucleic Acid

Based Lab-on-a-Chip Diagnostic System. Sci Rep. Springer US; 2020;10:1–9.

6. Neuner EA, Yeh JY, Hall GS, Sekeres J, Endimiani A, Bonomo RA, et al. Treatment

and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream

infections. Diagn Microbiol Infect Dis. 2011;69:357–62.

7. Bleumin D, Cohen MJ, Moranne O, Esnault VLM, Benenson S, Paltiel O, et al.

Carbapenem-resistant Klebsiella pneumoniae is associated with poor outcome in

hemodialysis patients. J Infect. Elsevier Ltd; 2012;65:318–25.

8. Otter JA, Burgess P, Davies F, Mookerjee S, Singleton J, Gilchrist M, et al. Counting

the cost of an outbreak of carbapenemase-producing Enterobacteriaceae: an

economic evaluation from a hospital perspective. Clin Microbiol Infect. Elsevier Ltd;

2017;23:188–96.

9. Codjoe F, Donkor E. Carbapenem Resistance: A Review. Med Sci. 2017;6:1.

10. Moloney E, Lee KW, Craig D, Allen AJ, Graziadio S, Power M, et al. A PCR-based

diagnostic testing strategy to identify carbapenemase-producing Enterobacteriaceae

carriers upon admission to UK hospitals: early economic modelling to assess costs

and consequences. Diagnostic Progn Res. Diagnostic and Prognostic Research;

2019;3:1–9.

11. Matsumura Y, Pitout JD. Recent advances in the laboratory detection of

carbapenemase-producing Enterobacteriaceae. Expert Rev Mol Diagn. Taylor &

Francis; 2016;16:783–94.

12. Reta DH, Tessema TS, Ashenef AS, Desta AF, Labisso WL, Gizaw ST, et al.

Molecular and Immunological Diagnostic Techniques of Medical Viruses. Int J

Microbiol. 2020;2020.

13. Collins GS, Moons KGM. Reporting of artificial intelligence prediction models.

Lancet. 2019;393:1577–9.

14. Moniri A, Miglietta L, Malpartida-Cardenas K, Pennisi I, Cacho-Soblechero M,

Moser N, et al. Amplification Curve Analysis: Data-Driven Multiplexing Using Real-

Time Digital PCR. Anal Chem. 2020;92:13134–43.

15. Moniri A, Rodriguez-Manzano J, Malpartida-Cardenas K, Yu LS, Didelot X,

Holmes A, et al. Framework for DNA Quantification and Outlier Detection Using

Multidimensional Standard Curves. Anal Chem. 2019;91:7426–34.

16. Rodriguez-Manzano J, Moniri A, Malpartida-Cardenas K, Dronavalli J, Davies F,

Holmes A, Georgiou P. Simultaneous single-channel multiplexing and quantification

of carbapenem-resistant genes using multidimensional standard curves. Anal Chem.

2019;91:2013–20.

17. Lim YJ, Park HY, Lee JY, Kwak SH, Kim MN, Sung H, et al. Clearance of

carbapenemase-producing Enterobacteriaceae (CPE) carriage: a comparative study

of NDM-1 and KPC CPE. Clin Microbiol Infect. Elsevier; 2018;24:1104.e5-1104.e8.

18. Maurer FP, Castelberg C, Quiblier C, Bloemberg G V., Hombach M. Evaluation of

carbapenemase screening and confirmation tests with Enterobacteriaceae and

development of a practical diagnostic algorithm. J Clin Microbiol. 2015;53:95–104.

19. Athamanolap P, Parekh V, Fraley SI, Agarwal V, Shin DJ, Jacobs MA, et al.

Trainable high resolution melt curve machine learning classifier for large-scale reliable

genotyping of sequence variants. PLoS One. 2014;9.

20. Edgar RC. MUSCLE: Multiple sequence alignment with high accuracy and high

throughput. Nucleic Acids Res. 2004;32:1792–7.

21.   multiple-primer-analyzer   @   www.thermofisher.com.   Available   from:

https://www.thermofisher.com/uk/en/home/brands/thermo-scientific/molecular-

biology/molecular-biology-learning-center/molecular-biology-resource-library/thermo-

scientific-web-tools/multiple-primer-analyzer.html

22. Corporation F. Digital PCR with the 37k IFC Using Gene-Specific Assays.

https://www.fluidigm.com/binaries/content/documents/fluidigm/resources/qdpcr-37k-

dpcr-qr-100-6896/qdpcr-37k-dpcr-qr-100-6896

23. Mercaldo ND, Lau KF, Zhou XH. Confidence intervals for predictive values with an

emphasis to case–control studies. Statistics in medicine. 2007;26:2170–83.

24. Huggett JF, Cowen S, Foy CA. Considerations for digital PCR as an accurate

molecular diagnostic tool. Clin Chem. 2015;61:79–88.

Table 1. Primer sets developed in this study for the 5-plex assay.

CPE target	Forward primer sequence (5'—3')	Reverse primer sequence (5'—3')	Amplicon size (bp)	Amplicon T_m (°C)
bla$_{IMP}$	CAGCAGAGYCTTTGCCAGATT	GCCACGYTCCACAAACCAA	203	86.5
bla$_{KPC}$	GGCTCAGGCGCAACTGTAA	GCCCAACTCCTTCAGCAACAA	273	95.5
bla$_{NDM}$	CGCGTGCTGKTGGTCGATA	GGCGAAAGTCAGGCTGTGTTG	240	96
bla$_{OXA-48}$	CGATTTGGGCGTGGTTAAGGAT	GTCGAGCCARAAACTGTCTAC	235	88.5
bla$_{VIM}$	CGAGGYAGAGGGGARCGAGATT	CTSTGCTTCCGGGTAGTGTT	275	94

459   *Table 2. Clinical Enterobacteriaceae isolates used in this study.*

Species (MALDI-TOF MS)	Carbapenemase gene	Number of isolates
Citrobacter spp.	bla_{IMP}	1
	bla_{KPC}	2
	bla_{NDM}	1
	bla_{OXA-48}	10
	bla_{VIM}	1
Enterobacter spp.	bla_{IMP}	20
	bla_{NDM}	7
	bla_{OXA-48}	2
	bla_{VIM}	2
Escherichia spp.	bla_{IMP}	7
	bla_{NDM}	14
	bla_{NDM} & bla_{OXA-48}	1
	bla_{OXA-48}	26
Klebsiella spp.	bla_{IMP}	15
	bla_{KPC}	6
	bla_{NDM}	51
	bla_{OXA-48}	45
	bla_{VIM}	3
Proteus mirabilis	bla_{NDM}	1
Pseudomonas aeruginosa	bla_{IMP}	2
	bla_{VIM}	2
Serratia marcescens	bla_{KPC}	1
	bla_{OXA-48}	1
Multiple species*	negative	32

460
461   *CPO-negative species: *Acinetobacter baumannii, Citrobacter freundii, Enterobacter spp., Escherichia*
462   *coli, Klebsiella pneumoniaea* and *Pseudomonas aeruginosa.*

463   *Table 3. Classification of clinical isolates based on ML-based MCA method*

Target	N	TP	TN[a]	FP	FN	SEN	SPE	Accuracy (CI)
*bla*IMP	45	45	32	0	0	100.0%	100.0%	100.0% (95.32 to 100.00%)
*bla*KPC	9	8	32	1[b]	0	100.0%	96.97%	97.56% (87.14 to 99.94%)
*bla*NDM	74	54	32	20[c]	0	100.0%	61.54%	81.13% (72.38 to 88.08%)
*bla*OXA-48	84	84	32	0	0	100.0%	100.0%	100.0% (96.87 to 100.00%)
*bla*VIM	8	8	32	0	0	100.0%	100.0%	100.0% (91.19 to 100.00%)
*bla*OXA-48 & *bla*NDM	1	1	32	0	0	100.0%	100.0%	100.0% (97.24 to 100.00)
Total	**221**	**200**	**32**	**21**	**0**	**100.0%**	**60.38%**	**91.70% (87.59 to 94.79%)**

464
Abbreviations - N: number of samples; TP: True Positive TN: True Negative; FP: False Positive, FN:
False Negative, SEN: Sensitivity, SPE: Specificity, CI: Confidence Interval.
[a]A total 32 negatives samples are considered across all the groups for sensitivity, specificity and
accuracy calculation
[b]This isolate was misclassified as *bla*NDM and *bla*KPC double infection
[c]These isolates were misclassified as *bla*NDM and *bla*KPC double infections

Table 4. Classification of clinical isolates based on ML-based AMCA method

Target	N	TP	TN[a]	FP	FN	SEN	SPE	Accuracy (CI)
bla$_{IMP}$	45	45	32	0	0	100.0%	100.0%	100.0% (95.32 to 100.00%)
bla$_{KPC}$	9	9	32	0	0	100.0%	100.0%	100.0% (91.40 to 100.00%)
bla$_{NDM}$	74	73	32	1[b]	0	100.0%	96.97%	99.06% (94.86% to 99.98%)
bla$_{OXA-48}$	84	84	32	0	0	100.0%	100.0%	100.0% (96.87 to 100.00%)
bla$_{VIM}$	8	8	32	0	0	100.0%	100.0%	100.0% (91.19 to 100.00%)
bla$_{OXA-48}$ & *bla*$_{NDM}$	1	1	32	0	0	100.0%	100.0%	100.0% (97.24 to 100.00)
Total	**221**	**220**	**32**	**1**	**0**	**100.0%**	**96.97%**	**99.60% (97.82 to 99.99%)**

472
473   Abbreviations - N: number of samples; TP: True Positive TN: True Negative; FP: False Positive, FN:
474   False Negative, SEN: Sensitivity, SPE: Specificity, CI: Confidence Interval.
475   [a]A total 32 negatives samples are considered across all the groups for sensitivity, specificity and
476   accuracy calculation
477   [b]This isolate was misclassified as *bla*$_{NDM}$ and *bla*$_{KPC}$ double infection

478
479
480 *Figure 1. Integration of data-driven approaches to standard diagnostic workflows. The blue*
481 *arrow indicates the conventional diagnosis pipeline from patient to result. The grey arrow on*
482 *the left indicates the most suitable genetic test is developed* in-silico, *comprising of specialised*
483 *assays capable of multi target detection in a single reaction in dPCR. The right grey arrow*
484 *indicates the AMCA methodology is applied for patient result analysis.*

Figure 2. Real-time amplification and melting curves obtained from the dPCR instrument. (a) Raw amplification curves at different concentrations; the black line represents the average trend of the kinetic. (b) Melting curves across the five different CPO; the black line represents the average trend of the thermodynamic. (c) Melting peak (T_m) distribution from the dPCR instrument, showing the probability density function (PDF) for each target.